ATF3-induced Activation of NF-κB Pathway Results in Acquired PARP Inhibitor Resistance in Pancreatic Adenocarcinoma

Yang Liu,Yizhi Cao,Pengyi Liu,Shuyu Zhai,Yihao Liu,Xiaomei Tang,Jiayu Lin,Minmin Shi,Debin Qi,Xiaxing Deng,Youwei Zhu,Weishen Wang,Baiyong Shen

DOI: https://doi.org/10.1007/s13402-023-00907-5

IF: 7.051

2024-01-01

Cellular Oncology

Abstract:Purpose Olaparib, an inhibitor of poly-(adenosine diphosphate-ribose) polymerase (PARP), has been shown to have anticancer benefits in patients with pancreatic cancer who have a germline mutation in BRCA1/2. However, resistance acquired on long-term exposure to olaparib significantly impedes clinical efficacy. Methods In this study, the chromatin accessibility and differentially expressed transcripts of parental and olaparib-resistant pancreatic cancer cell lines were assessed using the Assay for Transposase Accessible Chromatin with sequencing (ATAC-seq) and mRNA-seq. Detection of downstream genes regulated by transcription factors using ChIP (Chromatin immunoprecipitation assay). Results According to pathway enrichment analysis, differentially expressed genes in olaparib-resistant cells were remarkably enriched in the NF-κB signaling pathway. With ATAC-seq, we identified chromatin regions with higher accessibility in olaparib-resistant cells and predicted a series of important transcription factors. Among them, activating transcription factor 3 (ATF3) was significantly highly expressed. Functional experiments verified that inhibition of ATF3 suppressed the NF-κB pathway significantly and restored olaparib sensitivity in olaparib-resistant cells. Conclusion Experiments in vitro and in vivo indicate ATF3 enhances olaparib resistance through the NF-κB signaling pathway, suggesting that ATF3 could be employed as an olaparib sensitivity and prognostic indicator in patients with pancreatic cancer.